Prevalence of Growth Hormone Deficiency in Adults with Pituitary Adenomas
In this article, the authors analyzed the data of patients with pituitary tumors, of which 35 (87.5 %) suffered from growth hormone deficiency (GHD) in adults with neuroendocrine complications. Specific to GHD is a group of symptoms of mental and emotional disorders, which is determined based on a questionnaire. According to the treatment mode, there were 3 groups of patients on conservative treatment (n = 15), after surgery (n = 20), after radiotherapy and conservative or surgical treatment (n = 5). The control group consisted of 20 healthy age-matched individuals. Study of the quality of life in patients with GHD on the basis of a questionnaire (QoL) revealed the highest average score in these patients compared to the healthy group (p < 0.01), indicating a significant reduction of psychoemotional status in patients with GHD. It was found that GHD in adult patients with different formations of the sellar region was identified in 87.5 % of cases (35 patients out of 40 surveyed). The peculiarity of the clinical manifestations of GHD in adults is a significant deterioration of the mental and emotional state of patients on the background of neuroendocrine disorders.
Kane LA, Leinung MC, Scheithauer BW, Bergstralh EJ, Laws ER, Jr, Groover RV, et al. Pituitary adenomas in childhood and adolescence. J Clin Endocrinol Metab. 1994;79:1135-1140.
Artese R, D'Osvaldo DH, Molocznik I, Benencia H, Oviedo J, Burdman JA, et al. Pituitary tumors in adolescent patients. Neurol Res. 1998;20:415-417.
Abe T, Tara LA, Ludecke DK. Growth hormone-secreting pituitary adenomas in childhood and adolescence: features and results of transnasal surgery. Neurosurgery. 1999;45:1-10.
Rix M, Laurberg P, Hoejberg AS, Brock-Jacobsen B. Pegvisomant therapy in pituitary gigantism: successful treatment in a 12-year-old girl. Eur J Endocrinol. 2005;153:195-201.
Pandey P, Ojha BK, Mahapatra AK. Pediatric pituitary adenoma: a series of 42 patients. J Clin Neurosci.2005;12:124-127.
Kim HY, Jung HW, Lee J, Yoon JY, Lee YA, Shin CH, et al. Childhood onset pituitary adenoma: clinical presentations and outcomes of 24 cases. Ann Pediatr Endocrinol Metab. 2012;17:82-91.
Melmed S. Medical progress: acromegaly. N Engl J Med. 2006;355:2558-2573.
Sata A, Ho KK. Growth hormone measurements in the diagnosis and monitoring of acromegaly.Pituitary. 2007;10:165-172.
Ayuk J, Stewart SE, Stewart PM, Sheppard MC. European Sandostatin LAR Group. Efficacy of Sandostatin LAR (long-acting somatostatin analogue) is similar in patients with untreated acromegaly and in those previously treated with surgery and/or radiotherapy. Clin Endocrinol (Oxf) 2004;60:375-381.
Bevan JS, Atkin SL, Atkinson AB, Bouloux PM, Hanna F, Harris PE, et al. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. J Clin Endocrinol Metab.2002;87:4554-4563.
This work is licensed under a Creative Commons Attribution 4.0 International License.
© "Publishing House "Zaslavsky", 1997-2019